In patients with persistent atrial fibrillation, those receiving pulsed field ablation as first-line therapy had less risk ...

Guidelines recommend a trial of antiarrhythmic drugs before catheter ablation for persistent atrial fibrillation. Whether pulsed field ablation (PFA) may be a preferred initial treatment is ...

AVANT GUARD trial meets expectations despite pause for safety modifications ...

A minimally invasive heart procedure may be a better first-line treatment than medication for people living with advanced ...

A major clinical trial has found Boston Scientific’s Farapulse pulsed-field ablation nearly doubles the success rate of treating persistent atrial fibrillation compared with medication. One year after ...

Boston Scientific, Abbott and Medtronic shared new cardiac device data at the annual Heart Rhythm Society meeting, where ...

Real-world data presented at HRS 2026 add to the body of evidence supporting a shift away from short-duration Holter monitoring toward up to 14 ...

In the single-arm FULCRUM-VT trial, 59% of patients remained free of recurrent VT at 6 months, with less amiodarone use.

Two retrospective studies detected arrhythmias beyond 48 hours in 30% of patients post cardiac ablation and in 60% of ...

Over the last weekend, Chicago played host to the 2026 edition of the Heart Rhythm Society's annual conference (HRS 2026).

There are both clinical and economic implications, as payers have been discouraging ablation in this population, one expert ...